Thomas Boyer

Summary

Affiliation: University of Arizona
Country: USA

Publications

  1. ncbi Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1
    Thomas D Boyer
    Liver Research Institute, Department of Internal Medicine, University of Arizona College of Medicine, Tucson, AZ 85724, USA
    Liver Transpl 17:1328-32. 2011
  2. ncbi Transjugular intrahepatic portosystemic shunt in the management of complications of portal hypertension
    Thomas D Boyer
    Liver Research Institute, AHSC 245136, Room 309, 1501 North Campbell Avenue, Tucson, AZ 85724, USA
    Curr Gastroenterol Rep 10:30-5. 2008
  3. ncbi American Association for the Study of Liver Diseases Practice Guidelines: the role of transjugular intrahepatic portosystemic shunt creation in the management of portal hypertension
    Thomas D Boyer
    Liver Research Institute, University of Arizona School of Medicine, AHSC 245136, Tucson, 85750, USA
    J Vasc Interv Radiol 16:615-29. 2005
  4. ncbi Cost of preventing variceal rebleeding with transjugular intrahepatic portal systemic shunt and distal splenorenal shunt
    Thomas D Boyer
    Department of Medicine, University of Arizona, Liver Research Institute, Tucson, AZ 85724, USA
    J Hepatol 48:407-14. 2008
  5. ncbi The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension
    Thomas D Boyer
    Liver Research Institute, University of Arizona School of Medicine, Tucson, AZ 85750, USA
    Hepatology 41:386-400. 2005
  6. ncbi Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics
    Thomas D Boyer
    Dept of Medicine, University of Arizona, College of Medicine, Tucson, AZ, United States
    J Hepatol 55:315-21. 2011
  7. ncbi A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome
    Arun J Sanyal
    Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
    Gastroenterology 134:1360-8. 2008
  8. ncbi Identification of a short form of ubiquitin-specific protease 3 that is a repressor of rat glutathione S-transferase gene expression
    Richard Whalen
    The University of Arizona Liver Research Institute, College of Medicine, University of Arizona, Tucson, AZ 85724 5136, USA
    Biochem J 394:519-26. 2006
  9. ncbi Changing clinical practice with measurements of portal pressure
    Thomas D Boyer
    University of Arizona School of Medicine and Liver Research Institute, Tucson, AZ 85724, USA
    Hepatology 39:283-5. 2004
  10. ncbi Decreased expression levels of rat liver glutathione S-transferase A2 and albumin during the acute phase response are mediated by HNF1 (hepatic nuclear factor 1) and IL6DEX-NP
    Richard Whalen
    Liver Research Institute, University of Arizona School of Medicine, AHSC 245136, 1501 N Campbell Ave, Tucson, AZ 85724 5136, U S A
    Biochem J 377:763-8. 2004

Research Grants

  1. FACTORS IN THE PREVENTION OF TOXIC LIVER INJURY
    Thomas Boyer; Fiscal Year: 2003
  2. FACTORS IN THE PREVENTION OF TOXIC LIVER INJURY
    Thomas Boyer; Fiscal Year: 2007

Detail Information

Publications22

  1. ncbi Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1
    Thomas D Boyer
    Liver Research Institute, Department of Internal Medicine, University of Arizona College of Medicine, Tucson, AZ 85724, USA
    Liver Transpl 17:1328-32. 2011
    ..For patients not undergoing transplantation, HRS reversal with terlipressin and/or albumin improves survival...
  2. ncbi Transjugular intrahepatic portosystemic shunt in the management of complications of portal hypertension
    Thomas D Boyer
    Liver Research Institute, AHSC 245136, Room 309, 1501 North Campbell Avenue, Tucson, AZ 85724, USA
    Curr Gastroenterol Rep 10:30-5. 2008
    ..The role of TIPS in the treatment of hepatorenal syndrome is unclear; currently only patients with type 2 hepatorenal syndrome should be considered candidates for TIPS...
  3. ncbi American Association for the Study of Liver Diseases Practice Guidelines: the role of transjugular intrahepatic portosystemic shunt creation in the management of portal hypertension
    Thomas D Boyer
    Liver Research Institute, University of Arizona School of Medicine, AHSC 245136, Tucson, 85750, USA
    J Vasc Interv Radiol 16:615-29. 2005
  4. ncbi Cost of preventing variceal rebleeding with transjugular intrahepatic portal systemic shunt and distal splenorenal shunt
    Thomas D Boyer
    Department of Medicine, University of Arizona, Liver Research Institute, Tucson, AZ 85724, USA
    J Hepatol 48:407-14. 2008
    ..We examined the cost and cost effectiveness of distal splenorenal shunt (DSRS) and transjugular intrahepatic portosystemic shunt (TIPS) in the prevention of variceal rebleeding...
  5. ncbi The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension
    Thomas D Boyer
    Liver Research Institute, University of Arizona School of Medicine, Tucson, AZ 85750, USA
    Hepatology 41:386-400. 2005
  6. ncbi Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics
    Thomas D Boyer
    Dept of Medicine, University of Arizona, College of Medicine, Tucson, AZ, United States
    J Hepatol 55:315-21. 2011
    ..However, only about 1/3 of patients respond to treatment, therefore, predictors of response and survival would help identify the patients most likely to benefit from treatment...
  7. ncbi A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome
    Arun J Sanyal
    Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
    Gastroenterology 134:1360-8. 2008
    ..The aim of this study was to evaluate the efficacy and safety of terlipressin, a systemic arterial vasoconstrictor, for cirrhosis type 1 HRS...
  8. ncbi Identification of a short form of ubiquitin-specific protease 3 that is a repressor of rat glutathione S-transferase gene expression
    Richard Whalen
    The University of Arizona Liver Research Institute, College of Medicine, University of Arizona, Tucson, AZ 85724 5136, USA
    Biochem J 394:519-26. 2006
    ..We believe that the short form of USP3 is IL6DEX-NP and that it may play an important role in the negative regulation of proteins during the acute-phase response...
  9. ncbi Changing clinical practice with measurements of portal pressure
    Thomas D Boyer
    University of Arizona School of Medicine and Liver Research Institute, Tucson, AZ 85724, USA
    Hepatology 39:283-5. 2004
  10. ncbi Decreased expression levels of rat liver glutathione S-transferase A2 and albumin during the acute phase response are mediated by HNF1 (hepatic nuclear factor 1) and IL6DEX-NP
    Richard Whalen
    Liver Research Institute, University of Arizona School of Medicine, AHSC 245136, 1501 N Campbell Ave, Tucson, AZ 85724 5136, U S A
    Biochem J 377:763-8. 2004
    ..Later persistent decreases in transcriptional rate of rGSTA2 and to a lesser extent albumin are due to increased IL6DEX-NP binding. IL6DEX-NP appears to be an important negative regulator of gene expression in vitro and in vivo...
  11. ncbi Transjugular intrahepatic portosystemic shunt: current status
    Thomas D Boyer
    Department of Medicine, University of Arizona College of Medicine, Tucson, 85724, USA
    Gastroenterology 124:1700-10. 2003
    ..Despite the apparent efficacy of TIPS in many of these situations, its use should be limited to salvage therapy pending the publication of controlled trials showing it is a better treatment than other forms of therapy...
  12. ncbi Alcohol consumption by cirrhotic subjects: patterns of use and effects on liver function
    Michael R Lucey
    Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792 5124, USA
    Am J Gastroenterol 103:1698-706. 2008
    ....
  13. ncbi Survival of Clostridium perfringens sepsis in a liver transplant recipient
    Geraldine C Diaz
    Department of Anesthesiology, University of Arizona, Tucson, AZ, USA
    Liver Transpl 15:1469-72. 2009
    ..Herein, we describe the first documented survivor of C. perfringens sepsis following OLT managed without laparotomy or emergent ReTx...
  14. ncbi Characterization of the molecular forms of glutathione S-transferase P1 in human gastric cancer cells (Kato III) and in normal human erythrocytes
    Perungavar N Ranganathan
    The University of Arizona Liver Research Institute, 6309 AHSC, POB 245136, 1501 N Campbell Ave, Tucson, AZ 85724 5136, USA
    Biochem J 386:525-33. 2005
    ..Therefore normal and malignant human cells contain GSTP1 monomers with post-translational modifications, and it is likely that GSTP1 monomers regulate JNK activity in human cells in the same manner as in rodent cells...
  15. ncbi Transjugular intrahepatic portosystemic shunt (TIPS): its time has come
    Thomas D Boyer
    J Clin Gastroenterol 42:437-8. 2008
  16. ncbi Distal splenorenal shunt versus transjugular intrahepatic portal systematic shunt for variceal bleeding: a randomized trial
    J Michael Henderson
    Department of Surgery, Cleveland Clinic, Cleveland, Ohio, USA
    Gastroenterology 130:1643-51. 2006
    ..This prospective randomized trial tested the hypothesis that patients receiving distal splenorenal shunts (DSRS) would have significantly lower rebleeding and encephalopathy rates than TIPS in management of refractory variceal bleeding...
  17. ncbi Wedged hepatic vein pressure (WHVP): ready for prime time
    Thomas D Boyer
    Hepatology 43:405-6. 2006
  18. ncbi Primary prophylaxis against variceal bleeding: beta-blockers, endoscopic ligation, or both?
    Naga Chalasani
    Am J Gastroenterol 100:805-7. 2005
    ..Further study is required to determine if VBL in combination with beta-blockers is more effective than the beta-blockers alone...
  19. ncbi Mechanism of negative regulation of rat glutathione S-transferase A2 by the cytokine interleukin 6
    Susan H Voss
    Department of Pathology, Emory University School of Medicine, Atlanta, GA 30322, USA
    Biochem J 365:229-37. 2002
    ..The protein may be an important negative regulator of transcription during the acute-phase response...
  20. ncbi Clinical trials for variceal bleeding: and the winner is--the patient
    Thomas D Boyer
    Liver Transpl 13:1212-3. 2007
  21. ncbi Primary prophylaxis for variceal bleeding: are we there yet?
    Thomas D Boyer
    Gastroenterology 128:1120-2. 2005
  22. ncbi Screening in liver disease: report of an AASLD clinical workshop
    Paul C Adams
    London Health Sciences Centre, London, Ontario, Canada
    Hepatology 39:1204-12. 2004
    ..Future screening programs require careful planning and implementation to balance the benefits, risks, and cost-effectiveness. This review outlines the concepts of screening and their application to a broad range of liver diseases...

Research Grants6

  1. FACTORS IN THE PREVENTION OF TOXIC LIVER INJURY
    Thomas Boyer; Fiscal Year: 2003
    ..How phenobarbital selectively stabilizes mRNA in perivenous hepatocytes will be examined further. ..
  2. FACTORS IN THE PREVENTION OF TOXIC LIVER INJURY
    Thomas Boyer; Fiscal Year: 2007
    ..The studies will clarify why expression of certain proteins fall during the acute phase response. ..